Interleukin-2 therapy for advanced renal cell carcinoma: Radiographic evaluation of response and complications Academic Article uri icon


MeSH Major

  • Carcinoma, Renal Cell
  • Interleukin-2
  • Kidney Neoplasms
  • Thoracic Neoplasms


  • To evaluate the radiographic manifestations of the response of intrathoracic metastases to and the toxicity of interleukin-2 (IL-2) therapy, the chest radiographs and computed tomographic scans of 43 patients receiving 103 cycles of IL-2 treatment and lymphokine-activated killer cells for advanced renal cell carcinoma were reviewed. Among these 43 patients, 31 could be assessed for response of metastatic disease: Complete response was seen in one (3%), partial response in 11 (36%), mixed response in nine (29%), progressive disease in five (16%), and stable disease in five (16%). In 103 treatment cycles radiographic evidence of toxicity included pleural effusions (45.6%), pulmonary edema (21.4%), increased cardiothoracic ratio (16.5%), increased azygos vein diameter (9.7%), pericardial effusion (5.8%), and hilar lymphadenopathy (1.0%). These toxic effects could be distinguished from metastatic disease by a temporal relationship to treatment cycles. A favorable response to IL-2 therapy was significantly correlated (P less than .001) with the presence of pleural effusions.

publication date

  • January 1990



  • Academic Article



  • eng

PubMed ID

  • 2399311

Additional Document Info

start page

  • 127

end page

  • 31


  • 177


  • 1